
“We’ll have a file in the US hopefully before the end of the year,” Erck said.
If the FDA gives the green light, the first 100 million doses of the protein-based vaccine will be ready to ship following authorization, Erck said.
“In the US, the primary market I think in 2022 is going to be to supply a vaccine, our normal two-dose regimen, to a lot of people who have been hesitant to get other vaccines,” Erck said. “And to provide a booster.”
The Novavax coronavirus vaccine could be used to boost someone who originally received the Pfizer/BioNTech, Moderna or Johnson & Johnson vaccines, Erck said.
“We’ve actually filed in nine regulatory agencies just in the past half-dozen weeks,” Erck said. “And that resulted in our first one where we got approval.”